CV
NASDAQCapsoVision Inc.
News25/Ratings2
News · 26 weeks38-80%
2025-10-262026-04-19
Mix1990d
- Insider9(47%)
- SEC Filings6(32%)
- Offering2(11%)
- Other1(5%)
- Earnings1(5%)
Latest news
25 items- SECSEC Form EFFECT filed by CapsoVision Inc.EFFECT - CapsoVision, Inc (0001378325) (Filer)
- SECSEC Form S-1 filed by CapsoVision Inc.S-1 - CapsoVision, Inc (0001378325) (Filer)
- INSIDERSEC Form 3 filed by new insider Shen Ching Hang3 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERSEC Form 3 filed by new insider Harari Eliyahou Et Al3 - CapsoVision, Inc (0001378325) (Issuer)
- SECSEC Form 10-K filed by CapsoVision Inc.10-K - CapsoVision, Inc (0001378325) (Filer)
- SECCapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - CapsoVision, Inc (0001378325) (Filer)
- PRCapsoVision Reports Fourth Quarter and Full Year 2025 Financial ResultsSARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Fourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024.New accounts grew 16% in the fourth quarter of 2025 over the comparable quarter in 2024. Full year 2025 new accounts grew 21% compared to full year 2024.CapsoCam Plus® used by over 161,000 patients as of
- INSIDERSEC Form 4 filed by Tsai Chen Lung4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERSEC Form 4 filed by Kuo Hui Ying4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERSEC Form 4 filed by King Wen-Herng Henry4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERSEC Form 4 filed by Imperial Joanne Carol4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERSEC Form 4 filed by Harari Michele4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERSEC Form 4 filed by Gouw Julia S4 - CapsoVision, Inc (0001378325) (Issuer)
- SECCapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - CapsoVision, Inc (0001378325) (Filer)
- PRCapsoVision Announces $14 Million Private Placement FinancingSARATOGA, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (the "Company") (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the closing of a $14 million private placement in public equity financing (the "Private Placement") pursuant to a securities purchase agreement entered into by the Company with selected accredited investors on March 16, 2026 for such investors to purchase shares (the "Shares") of common stock of the Company. Pursuant to the securities purchase agreement, the Company has agreed to sell 2,867,089 shares of common stock of the Company, with par value $0.001 per
- SECSEC Form 8-K filed by CapsoVision Inc.8-K - CapsoVision, Inc (0001378325) (Filer)
- PRCapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and refere
- PRCapsoVision to Participate in the 38th Annual ROTH Conference- Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 - SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the 38th Annual ROTH Conference on Monday, March 23, 2026 in Dana Point, CA. Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Monday, March 23, 2026, at 10:30–10:55 am PT The fireside chat will
- INSIDERAmendment: Director Tsai Chen Lung bought $83 worth of shares (20 units at $4.17) (SEC Form 4)4/A - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector Harari Michele exercised 2,887 shares at a strike of $10.69, increasing direct ownership by 5% to 59,043 units (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector Gouw Julia S exercised 2,887 shares at a strike of $10.69 (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector Imperial Joanne Carol exercised 2,887 shares at a strike of $10.69 (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector King Wen-Herng Henry exercised 2,887 shares at a strike of $10.69, increasing direct ownership by 14% to 23,597 units (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector Kuo Hui Ying exercised 2,887 shares at a strike of $10.69, increasing direct ownership by 28% to 13,241 units (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)
- INSIDERDirector Tsai Chen Lung exercised 2,887 shares at a strike of $10.69 (SEC Form 4)4 - CapsoVision, Inc (0001378325) (Issuer)